bluebird bio

bluebird bio

Biotechnology Research

Somerville, Massachusetts 137,167 followers

Pursuing curative gene therapies to give patients and their families more bluebird days.

About us

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines

Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Somerville, Massachusetts
Type
Public Company
Founded
1993
Specialties
gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy

Locations

  • Primary

    455 Grand Union Blvd

    Somerville, Massachusetts 02145, US

    Get directions

Employees at bluebird bio

Updates

Similar pages

Browse jobs

Stock

BLUE

NASDAQ

20 minutes delay

$0.48

-0.012 (-2.338%)

Open
0.485
Low
0.48
High
0.499

Data from Refinitiv

See more info on Bing

Funding

bluebird bio 17 total rounds

Last Round

Post IPO debt

US$ 75.0M

See more info on crunchbase